Agomelatine: an agent against anhedonia and abulia?

Journal of Neural Transmission

Volumn 122, Issue , 2015, Pages 3-7

  Thome, J ^a   Foley, P ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Antidepressant; Depression; Melatonin; Psychopharmacology

Indexed keywords

AGOMELATINE; ACETAMIDE DERIVATIVE; HYPNOTIC SEDATIVE AGENT;

ABULIA; ANHEDONIA; ANTIDEPRESSANT ACTIVITY; CLINICAL STUDY; DOPAMINERGIC ACTIVITY; DRUG MECHANISM; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; MOOD DISORDERS;

ACETAMIDES; ANHEDONIA; HUMANS; HYPNOTICS AND SEDATIVES; MOOD DISORDERS;

EID: 84938991641     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1126-6     Document Type: Review

References (50)

1. Bakheit AM, Fletcher K, Brennan A (2011) Successful treatment of severe abulia with co-beneldopa. NeuroRehabilitation 29:347–351
2. Barrett K (1991) Treating organic abulia with bromocriptine and lisuride: four case studies. J Neurol Neurosurg Psychiatry 54:718–721
3. Berrios GE, Gili M (1995) Will and its disorders: a conceptual history. Hist Psychiatry 6:87–104
4. Blier P, El Monsari M (2013) Serotonin and beyond: therapeutics for major depression. Phil Trans R Soc B 368:20120536
5. Chenu F, El Mansari M, Blier P (2013) Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology 38:275–284
6. Corruble E, de Bodinat C, Belaïdi C, Goodwin GM (2013) Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol 16:2219–2234
7. Dahale AB, Narayanaswamy JC, Venkatasubramanian G, Bagewadi VI (2013) Successful use of agomelatine and venlafaxine combination in major depression. Gen Hosp Psychiatry. doi:10.1016/j.genhosppsych.2013.09.001 (in press)
8. De Berardis D, Valchera A, Fornaro M, Serroni N, Marini S, Moschetta FS, Martinotti G, Di Giannantonio M (2013a) Agomelatine reversal of escitalopram-induced apathy: a case report. Psychiatry Clin Neurosci 67:190–191
9. De Berardis D, Marini S, Fornaro M, Srinivasan V, Iasevoli F, Tomasetti C, Valchera A, Perna G, Quera-Salva M-A, Martinotti G, di Giannantonio M (2013b) the melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci 14:12458–12483
10. De Berardis D, Conti CM, Marini S, Ferri F, Iasevoli F, Valchera A, Fornaro M, Cavuto M, Srinivasan V, Perna G, Carano A, Piersanti M, Martinotti G, Di Giannantonio M (2013c) Is there a role for agomelatine in the treatment of anxiety disorders?a review of published data. Int J Immunopathol Pharmacol 26:299–304
11. Demyttenaere K, Corruble E, Hale A, Quera-Salva MA, Picarel-Blanchot F, Kasper S (2013) A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr 18:163–170
12. Di Giannantonio M, Martinotti G (2012) Anhedonia and major depression: the role of agomelatine. Eur Neuropsychopharmacol 22(Suppl 3):S505–S510
13. Di Giannantonio M, Di Iorio G, Guglielmo R, De Berardis D, Conti CM, Acciavatti T, Cornelio M, Martinotti G (2011) Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents 25:109–114
14. Fonken LK, Nelson RJ (2013) Dim light at night increases depressive-like responses in male C3H/HeNHsd mice. Behav Brain Res 243:74–78
15. Fornaro M, McCarthy MJ, De Berardis D, De Pasquale C, Tabaton M, Martino M, Colicchio S, Cattaneo CI, D’Angelo E, Fornaro P (2013) Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open-label study. Neuropsychiat Dis Treatment 9:243–251
16. Förstl H, Sahakian B (1991) A psychiatric presentation of abulia—three cases of left frontal lobe ischaemia and atrophy. J R Soc Med 84:89–91
17. Fuchs E, Simon M, Schmelting B (2006) Pharmacology of a new antidepressant: benefits of the implications of the melatonergic system. Int J Clin Psychopharmacol 2006(Suppl 1):S17–S20
18. Ghoshal S, Gokhale S, Rebovich G, Caplan LR (2011) The neurology of decreased activity: abulia. Rev Neurol Dis 8:55–67
19. Heun R, Ahokas A, Boyer P, Giménez-Montesinos N, Pontes-Soares F, Olivier V (2013) Agomelatine Study Group The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry 74:587–594
20. Howland RH (2009) Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat 5:563–576
21. Kasper S, Hajak G (2013) The efficacy of agomelatine in previously-treated depressed patients. Eur Neuropsychopharmacol 23:814–821
22. Kennedy SH (2009) Agomelatine: efficacy at each phase of antidepressant treatment. CNS Drugs 23(Suppl 2):41–47
23. Kennedy SH, Rizvi SJ (2010) Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 24:479–499
24. Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C (2013) Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 203:179–187
25. Lanfumey L, Mongeau R, Hamon M (2013) Biological rhythms and melatonin in mood disorders and their treatments. Pharmacol Ther 138:176–184
26. Mairesse J, Silletti V, Laloux C, Zuena AR, Giovine A, Consolazione M, van Camp G, Malagodi M, Gaetani S, Cianci S, Catalani A, Mennuni G, Mazzetta A, van Reeth O, Gabriel C, Mocaër E, Nicoletti F, Morley-Fletcher S, Maccari S (2012) Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats. Int J Neuropsychopharmacol 6:1–16
27. Marin RS, Wilkosz PA (2005) Disorders of diminished motivation. J Head Trauma Rehabil 20:377–388
28. Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, Onofrj M, Janiri L, Di Giannantonio M (2012) Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol 32:487–491
29. Milano W, De Rosa M, Milano L, Riccio A, Sanseverino B, Capasso A (2013) Successful treatment with agomelatine in NES: a series of five cases. Open Neurol J. 7:32–37
30. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (2003) The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306:954–964
31. Miller DB, O’Callaghan JP (2013) Personalized medicine in major depressive disorder – opportunities and pitfalls. Metabolism 62(Suppl 1):S34–S39
32. O’Brien EM, Chelminski I, Young D, Dalrymple K, Hrabosky J, Zimmerman M (2011) Severe insomnia is associated with more severe presentation and greater functional deficits in depression. J Psychiatr Res 45:1101–1105
33. Pecenak J, Novotny V (2013) Agomelatine as monotherapy for major depression: an outpatient, open-label study. Neuropsychiatr Dis Treat 9:1595–1604
34. Rainer Q, Xia L, Guilloux JP, Gabriel C, Mocaër E, Hen R, Enhamre E, Gardier AM, David DJ (2011) Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int J Neuropsychopharmacol 2011:1–15
35. Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM (1995) Dose dependent effects of S-20098, a melatonin agonist on a direction of re-entrainment of rat circadian activity rhythms. Psychopharmacol (Berlin) 118:385–390
36. Ribot TA (1896) La psychologie des sentiments. Felix Alcan, Paris
37. Sansone RA, Sansone LA (2011) Agomelatine: a novel antidepressant. Innov Clin Neurosci 8:10–14
38. Sinnott C, Morris M (2013) Agomelatine: clinical experience and adherence to EMA recommendations for a novel antidepressant. Ir Med J 106:52–54
39. Souery D, Papakostas GI, Trivedi MH (2006) Treatment-resistant depression. J Clin Psychiatry 67(Suppl 6):16–22
40. Stahl SM (2007) Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol 10:575–578
41. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A (2010) Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 71:616–626
42. Stein DJ, Picarel-Blanchot F, Kennedy SH (2013) Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol 28:151–159
43. Štuhec M (2013) Agomelatine-induced hepatotoxicity. Wien Klin Wochenschr 125:225–226
44. Sunderajan P, Gaynes BN, Wisniewski SR, Miyahara S, Fava M, Akingbala F, DeVeaugh-Geiss J, Rush AJ, Trivedi MH (2010) Insomnia in patients with depression: a STAR*D report. CNS Spectr 15:394–404
45. Tapia-Osorio A, Salgado-Delgado R, Angeles-Castellanos M, Escobar C (2013) Disruption of circadian rhythms due to chronic constant light leads to depressive and anxiety-like behaviors in the rat. Behav Brain Res 252:1–9
46. Treadway MT, Zald DH (2011) Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 35:537–555
47. Vijayaraghavan L, Krishnamoorthy ES, Brown RG, Trimble MR (2002) Abulia: a Delphi survey of British neurologists and psychiatrists. Mov Disord 17:1052–1057
48. Warden D, Trivedi MH, Fava M, Wisniewski SR (2007) The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 9:449–459
49. Weizman S, Gonda X, Dome P, Faludi G (2012) Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder. Neuropsychopharmacol Hung 14:87–101
50. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A (2010) Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 30:135–144